Navigation Links
Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
Date:8/21/2008

Research Study Will Explore Therapeutic Cellular Platform Utilizing Cord Blood and Menstrual Blood Derived Stem Cells in the Formation of Emergent

Vascular Structures

OLDSMAR, Fla., Aug. 21 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. and EndGenitor Technologies, Inc. are pleased to announce a new research collaboration to co-develop a combined cellular platform therapeutic for rapidly forming vasculature in injured tissues. Currently, intense research into the mechanisms of initiation of angiogenesis and the repair of damaged vasculature is underway in order to identify the participating molecular and cellular components involved. Greater understanding of this highly-complex process is paving the way to identify novel potential therapeutics for treating cancer and cardiovascular disease.

The research will focus on the utilization of cord blood and menstrual blood derived cells, known as ECFCs(R) and MenSCs, respectively. ECFCs(R) are cord blood-derived endothelial colony-forming cells. ECFCs(R) are currently in pre-clinical development by EndGenitor for cardiovascular and other therapeutic applications. MenSCs, which were discovered and developed by Cryo-Cell, are primitive mesenchymal progenitor cells found in menstrual blood and are easily retrievable without invasive techniques.

"We think the project has significant potential, as both ECFCs(R) and MenSCs contribute to angiogenesis in vivo, which underscores the importance of further study into the potential synergy of these cells in the formation of vasculature," said Dr. Julie Allickson, Vice President of Laboratory Operations and Research and Development at Cryo-Cell, which developed and maintains proprietary intellectual property (IP) on MenSCs.

"EndGenitor is extremely pleased to have the opportunity to partner with Cryo-Cell International in the development of its regenerative medicine product lines. The synergy resulting from Cryo-C
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
2. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
3. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
4. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
5. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
6. Yongye Biotechnology International Announces Second Quarter Results
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
9. Yongye Biotechnology International Retains CCG Investor Relations
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... report its first quarter 2015 results before the Nasdaq ... then host a live conference call and webcast to discuss ... morning, April 30, 2015 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1906 (US) or ...
(Date:4/23/2015)... FRANCISCO, Calif. , April 23, 2015  Veracyte, Inc. ... entered into a definitive agreement to sell approximately $40 ... Under the agreement, the investors will purchase an aggregate ... price of $8.15 per share, the closing stock price ... by new and existing investors, including Broadfin Capital, Camber ...
(Date:4/23/2015)... HOUSTON , April 23, 2015  Metanome, ... today announced the company has changed its name ... reflect Diversigen,s positioning as the single commercial source ... need to capitalize on the diverse opportunities of ... types that Diversigen accepts – including those that ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company ... States Patent and Trademark Office has issued 2 new ... US Pat. No. 8,986,727 was issued on March ... device for the sustained release of therapeutic agents. ... sustained (zero-order) release of large and small molecules for ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... June 2 NeoGenomics, Inc. (OTC Bulletin ... Sixth Annual Noble Financial Equity Conference at 12:30 PM ... the Seminole Hard Rock Hotel in Hollywood, FL. ... give a presentation regarding NeoGenomics, market positioning, financial performance, and ...
... Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company,s participation at two ... , , EVP ... SMID Cap Conference at the InterContinental Hotel in Boston, Mass. beginning at ... , , ...
... to be effective in making silicon-based electronics may be viable ... molecule thick. Researchers at the Max Plank Institute for Metals ... online in the journal Physical Review B on June 1. ... the basis for a host of extremely small and efficient ...
Cached Biology Technology:NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3Genoptix Announces Participation at June Investor Conferences 2
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... that have died in mass strandings in New Zealand ... a new study concludes, challenging a popular assumption that ... almost certain death because of familial ties. Using ... determined that both related and unrelated individuals were scattered ...
... , Francisella tularensis , the cause of tularemia ... considered a potential biological weapon because it is readily aerosolized ... humans. While a live attenuated vaccine strain has been ... understand the basis for its attenuated virulence. In an ...
... engineers are developing the right mix to reduce concrete,s ... biofuel byproducts. "The idea is to use bioethanol ... concrete as a partial replacement of cement," said Feraidon ... using these materials we can reduce the carbon footprint ...
Cached Biology News:Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3News tips from the journal mBio®, volume 4, issue 1 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: